Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

Summary

This study will evaluate the safety, toxicity and efficacy of talactoferrin in reducing the incidence of all nosocomial infections in prematurely-born infants.

Timeline

Start

2009-06

Primary completion

2012-03

Completion

2012-12

Outcome

Met primary endpoint

paper The rate of hospital-acquired infections was 50% lower in the TLf group compared with the placebo group (P < .04), PMID 27260839 ↗

Publications

• Sherman MP, Adamkin DH, Niklas V, Radmacher P, Sherman J, Wertheimer F, Petrak K. Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants. J Pediatr. 2016 Aug;175:68-73.e3. doi: 10.1016/j.jpeds.2016.04.084. Epub 2016 May 31.
• Sherman MP, Sherman J, Arcinue R, Niklas V. Randomized Control Trial of Human Recombinant Lactoferrin: A Substudy Reveals Effects on the Fecal Microbiome of Very Low Birth Weight Infants. J Pediatr. 2016 Jun;173 Suppl:S37-42. doi: 10.1016/j.jpeds.2016.02.074.

Drugs

Indications